GHRH analogue research
CJC-1295.
3 vendors · A$31–60
GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.
Live vendor register · sorted by price
Every vendor. Same compound, sorted ascending.
CJC-1295 · price-normalised
n = 5 vendors
01
QSC Peptides
VID-QSC-PEPTHPLC · MS · Janoshik
99%
7–14 days (CN warehouse) · Kit of 10 · from $220
A$31
02
QSC Peptides
VID-QSC-PEPTHPLC · MS · Janoshik
99%
5–7 days (domestic lane) · Kit of 10 · from $230
A$32
Representative literature
Research context. Recent peer-reviewed work.
2005 · Endocrinology
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats
2006 · J. Clin. Endocrinol. Metab.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006 · J. Clin. Endocrinol. Metab.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Long-form research guide
Weight Loss Research. Mechanism + protocols + safety.
Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models
Open the long-form guide for CJC-1295 →